Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease
Identifieur interne : 001933 ( Istex/Corpus ); précédent : 001932; suivant : 001934Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease
Auteurs : Theresa A. Zesiewicz ; Kelly L. Sullivan ; John L. Maldonado ; William O. Tatum ; Robert A. HauserSource :
- Movement Disorders [ 0885-3185 ] ; 2005-09.
English descriptors
- KwdEn :
Abstract
We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopa‐induced dyskinesias in Parkinson's disease (PD) in an open‐label pilot study. Nine PD patients who were experiencing peak‐dose dyskinesias for at least 25% of the awake day and were at least moderately disabling were treated with LEV in doses up to 3,000 mg for up to 60 days. The primary outcome measure was the percent of the awake day that patients spent on without dyskinesia or with nontroublesome dyskinesia (good on time). The mean dose of LEV at endpoint was 625 ± 277 mg/day. LEV significantly improved percent of the awake day on without dyskinesia or with nontroublesome dyskinesia at endpoint compared to baseline (43% ± 12% vs. 61% ± 17%; P = 0.02). Percent on time with troublesome dyskinesia decreased from 23% ± 10% at baseline to 11% ± 6% at endpoint, although not significantly. There was no significant increase in off time from baseline to endpoint. There was a 56% dropout rate, mostly due to somnolence. In PD patients who experienced peak‐dose dyskinesia for at least 25% of the awake day, LEV significantly improved on time without dyskinesia or with nontroublesome dyskinesia. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20563
Links to Exploration step
ISTEX:9C448C47012553C0CA49E602AB1F33011679209CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease</title><author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Maldonado, John L" sort="Maldonado, John L" uniqKey="Maldonado J" first="John L." last="Maldonado">John L. Maldonado</name><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>College of Public Health, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Tatum, William O" sort="Tatum, William O" uniqKey="Tatum W" first="William O." last="Tatum">William O. Tatum</name><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9C448C47012553C0CA49E602AB1F33011679209C</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20563</idno><idno type="url">https://api.istex.fr/document/9C448C47012553C0CA49E602AB1F33011679209C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001933</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease</title><author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Maldonado, John L" sort="Maldonado, John L" uniqKey="Maldonado J" first="John L." last="Maldonado">John L. Maldonado</name><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>College of Public Health, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Tatum, William O" sort="Tatum, William O" uniqKey="Tatum W" first="William O." last="Tatum">William O. Tatum</name><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-09">2005-09</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1205">1205</biblScope><biblScope unit="page" to="1209">1209</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">9C448C47012553C0CA49E602AB1F33011679209C</idno><idno type="DOI">10.1002/mds.20563</idno><idno type="ArticleID">MDS20563</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Keppra</term><term>Parkinson's disease</term><term>dyskinesia</term><term>levetiracetam</term><term>levodopa</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopa‐induced dyskinesias in Parkinson's disease (PD) in an open‐label pilot study. Nine PD patients who were experiencing peak‐dose dyskinesias for at least 25% of the awake day and were at least moderately disabling were treated with LEV in doses up to 3,000 mg for up to 60 days. The primary outcome measure was the percent of the awake day that patients spent on without dyskinesia or with nontroublesome dyskinesia (good on time). The mean dose of LEV at endpoint was 625 ± 277 mg/day. LEV significantly improved percent of the awake day on without dyskinesia or with nontroublesome dyskinesia at endpoint compared to baseline (43% ± 12% vs. 61% ± 17%; P = 0.02). Percent on time with troublesome dyskinesia decreased from 23% ± 10% at baseline to 11% ± 6% at endpoint, although not significantly. There was no significant increase in off time from baseline to endpoint. There was a 56% dropout rate, mostly due to somnolence. In PD patients who experienced peak‐dose dyskinesia for at least 25% of the awake day, LEV significantly improved on time without dyskinesia or with nontroublesome dyskinesia. © 2005 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Theresa A. Zesiewicz MD</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</json:string><json:string>Department of Neurology, University of South Florida, Tampa, Florida, USA</json:string></affiliations></json:item><json:item><name>Kelly L. Sullivan MSPH</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</json:string><json:string>Department of Neurology, University of South Florida, Tampa, Florida, USA</json:string></affiliations></json:item><json:item><name>John L. Maldonado BS</name><affiliations><json:string>Department of Neurology, University of South Florida, Tampa, Florida, USA</json:string><json:string>College of Public Health, University of South Florida, Tampa, Florida, USA</json:string></affiliations></json:item><json:item><name>William O. Tatum DO</name><affiliations><json:string>Department of Neurology, University of South Florida, Tampa, Florida, USA</json:string></affiliations></json:item><json:item><name>Robert A. Hauser MD</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</json:string><json:string>Department of Neurology, University of South Florida, Tampa, Florida, USA</json:string><json:string>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>levetiracetam</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Keppra</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dyskinesia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>levodopa</value></json:item></subject><language><json:string>eng</json:string></language><abstract>We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopa‐induced dyskinesias in Parkinson's disease (PD) in an open‐label pilot study. Nine PD patients who were experiencing peak‐dose dyskinesias for at least 25% of the awake day and were at least moderately disabling were treated with LEV in doses up to 3,000 mg for up to 60 days. The primary outcome measure was the percent of the awake day that patients spent on without dyskinesia or with nontroublesome dyskinesia (good on time). The mean dose of LEV at endpoint was 625 ± 277 mg/day. LEV significantly improved percent of the awake day on without dyskinesia or with nontroublesome dyskinesia at endpoint compared to baseline (43% ± 12% vs. 61% ± 17%; P = 0.02). Percent on time with troublesome dyskinesia decreased from 23% ± 10% at baseline to 11% ± 6% at endpoint, although not significantly. There was no significant increase in off time from baseline to endpoint. There was a 56% dropout rate, mostly due to somnolence. In PD patients who experienced peak‐dose dyskinesia for at least 25% of the awake day, LEV significantly improved on time without dyskinesia or with nontroublesome dyskinesia. © 2005 Movement Disorder Society</abstract><qualityIndicators><score>5.908</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1241</abstractCharCount><pdfWordCount>3484</pdfWordCount><pdfCharCount>21684</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>202</abstractWordCount></qualityIndicators><title>Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease</title><genre><json:string>Serial article</json:string></genre><host><volume>20</volume><pages><total>5</total><last>1209</last><first>1205</first></pages><issn><json:string>0885-3185</json:string></issn><issue>9</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2005</publicationDate><copyrightDate>2005</copyrightDate><doi><json:string>10.1002/mds.20563</json:string></doi><id>9C448C47012553C0CA49E602AB1F33011679209C</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/9C448C47012553C0CA49E602AB1F33011679209C/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/9C448C47012553C0CA49E602AB1F33011679209C/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/9C448C47012553C0CA49E602AB1F33011679209C/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2005</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease</title><author><persName><forename type="first">Theresa A.</forename><surname>Zesiewicz</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: University of South Florida, 12901 Bruce B. Downs Boulevard, MDC Box 55, Tampa, FL 33612</p></note><affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation></author><author><persName><forename type="first">Kelly L.</forename><surname>Sullivan</surname><roleName type="degree">MSPH</roleName></persName><affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation></author><author><persName><forename type="first">John L.</forename><surname>Maldonado</surname><roleName type="degree">BS</roleName></persName><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>College of Public Health, University of South Florida, Tampa, Florida, USA</affiliation></author><author><persName><forename type="first">William O.</forename><surname>Tatum</surname><roleName type="degree">DO</roleName></persName><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation></author><author><persName><forename type="first">Robert A.</forename><surname>Hauser</surname><roleName type="degree">MD</roleName></persName><affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-09"></date><biblScope unit="vol">20</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1205">1205</biblScope><biblScope unit="page" to="1209">1209</biblScope></imprint></monogr><idno type="istex">9C448C47012553C0CA49E602AB1F33011679209C</idno><idno type="DOI">10.1002/mds.20563</idno><idno type="ArticleID">MDS20563</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2005</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopa‐induced dyskinesias in Parkinson's disease (PD) in an open‐label pilot study. Nine PD patients who were experiencing peak‐dose dyskinesias for at least 25% of the awake day and were at least moderately disabling were treated with LEV in doses up to 3,000 mg for up to 60 days. The primary outcome measure was the percent of the awake day that patients spent on without dyskinesia or with nontroublesome dyskinesia (good on time). The mean dose of LEV at endpoint was 625 ± 277 mg/day. LEV significantly improved percent of the awake day on without dyskinesia or with nontroublesome dyskinesia at endpoint compared to baseline (43% ± 12% vs. 61% ± 17%; P = 0.02). Percent on time with troublesome dyskinesia decreased from 23% ± 10% at baseline to 11% ± 6% at endpoint, although not significantly. There was no significant increase in off time from baseline to endpoint. There was a 56% dropout rate, mostly due to somnolence. In PD patients who experienced peak‐dose dyskinesia for at least 25% of the awake day, LEV significantly improved on time without dyskinesia or with nontroublesome dyskinesia. © 2005 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>levetiracetam</term></item><item><term>Keppra</term></item><item><term>dyskinesia</term></item><item><term>Parkinson's disease</term></item><item><term>levodopa</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2004-08-17">Received</change><change when="2005-01-20">Registration</change><change when="2005-09">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/9C448C47012553C0CA49E602AB1F33011679209C/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="90"><doi origin="wiley" registered="yes">10.1002/mds.v20:9</doi><numberingGroup><numbering type="journalVolume" number="20">20</numbering><numbering type="journalIssue">9</numbering></numberingGroup><coverDate startDate="2005-09">September 2005</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="190" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20563</doi><idGroup><id type="unit" value="MDS20563"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2005 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2004-08-17"></event><event type="manuscriptRevised" date="2004-12-14"></event><event type="manuscriptAccepted" date="2005-01-20"></event><event type="publishedOnlineEarlyUnpaginated" date="2005-06-13"></event><event type="firstOnline" date="2005-06-13"></event><event type="publishedOnlineFinalForm" date="2005-08-22"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1205</numbering><numbering type="pageLast">1209</numbering></numberingGroup><correspondenceTo>University of South Florida, 12901 Bruce B. Downs Boulevard, MDC Box 55, Tampa, FL 33612</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20563.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="26"></count><count type="wordTotal" number="3312"></count></countGroup><titleGroup><title type="main" xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease</title><title type="short" xml:lang="en">Levetiracetam and <sc>L</sc>‐Dopa–Induced Dyskinesias</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Theresa A.</givenNames><familyName>Zesiewicz</familyName><degrees>MD</degrees></personName><contactDetails><email>tzesiewi@hsc.usf.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Kelly L.</givenNames><familyName>Sullivan</familyName><degrees>MSPH</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2 #af3"><personName><givenNames>John L.</givenNames><familyName>Maldonado</familyName><degrees>BS</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>William O.</givenNames><familyName>Tatum</familyName><degrees>DO</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1 #af2 #af4"><personName><givenNames>Robert A.</givenNames><familyName>Hauser</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>College of Public Health, University of South Florida, Tampa, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">levetiracetam</keyword><keyword xml:id="kwd2">Keppra</keyword><keyword xml:id="kwd3">dyskinesia</keyword><keyword xml:id="kwd4">Parkinson's disease</keyword><keyword xml:id="kwd5">levodopa</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopa‐induced dyskinesias in Parkinson's disease (PD) in an open‐label pilot study. Nine PD patients who were experiencing peak‐dose dyskinesias for at least 25% of the awake day and were at least moderately disabling were treated with LEV in doses up to 3,000 mg for up to 60 days. The primary outcome measure was the percent of the awake day that patients spent <i>on</i> without dyskinesia or with nontroublesome dyskinesia (good <i>on</i> time). The mean dose of LEV at endpoint was 625 ± 277 mg/day. LEV significantly improved percent of the awake day <i>on</i> without dyskinesia or with nontroublesome dyskinesia at endpoint compared to baseline (43% ± 12% vs. 61% ± 17%; <i>P</i> = 0.02). Percent <i>on</i> time with troublesome dyskinesia decreased from 23% ± 10% at baseline to 11% ± 6% at endpoint, although not significantly. There was no significant increase in <i>off</i> time from baseline to endpoint. There was a 56% dropout rate, mostly due to somnolence. In PD patients who experienced peak‐dose dyskinesia for at least 25% of the awake day, LEV significantly improved <i>on</i> time without dyskinesia or with nontroublesome dyskinesia. © 2005 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Levetiracetam and L‐Dopa–Induced Dyskinesias</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Theresa A.</namePart><namePart type="family">Zesiewicz</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><description>Correspondence: University of South Florida, 12901 Bruce B. Downs Boulevard, MDC Box 55, Tampa, FL 33612</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kelly L.</namePart><namePart type="family">Sullivan</namePart><namePart type="termsOfAddress">MSPH</namePart><affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">John L.</namePart><namePart type="family">Maldonado</namePart><namePart type="termsOfAddress">BS</namePart><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>College of Public Health, University of South Florida, Tampa, Florida, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">William O.</namePart><namePart type="family">Tatum</namePart><namePart type="termsOfAddress">DO</namePart><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Robert A.</namePart><namePart type="family">Hauser</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><affiliation>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2005-09</dateIssued><dateCaptured encoding="w3cdtf">2004-08-17</dateCaptured><dateValid encoding="w3cdtf">2005-01-20</dateValid><copyrightDate encoding="w3cdtf">2005</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">3</extent><extent unit="references">26</extent><extent unit="words">3312</extent></physicalDescription><abstract lang="en">We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopa‐induced dyskinesias in Parkinson's disease (PD) in an open‐label pilot study. Nine PD patients who were experiencing peak‐dose dyskinesias for at least 25% of the awake day and were at least moderately disabling were treated with LEV in doses up to 3,000 mg for up to 60 days. The primary outcome measure was the percent of the awake day that patients spent on without dyskinesia or with nontroublesome dyskinesia (good on time). The mean dose of LEV at endpoint was 625 ± 277 mg/day. LEV significantly improved percent of the awake day on without dyskinesia or with nontroublesome dyskinesia at endpoint compared to baseline (43% ± 12% vs. 61% ± 17%; P = 0.02). Percent on time with troublesome dyskinesia decreased from 23% ± 10% at baseline to 11% ± 6% at endpoint, although not significantly. There was no significant increase in off time from baseline to endpoint. There was a 56% dropout rate, mostly due to somnolence. In PD patients who experienced peak‐dose dyskinesia for at least 25% of the awake day, LEV significantly improved on time without dyskinesia or with nontroublesome dyskinesia. © 2005 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>levetiracetam</topic><topic>Keppra</topic><topic>dyskinesia</topic><topic>Parkinson's disease</topic><topic>levodopa</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>9</number></detail><extent unit="pages"><start>1205</start><end>1209</end><total>5</total></extent></part></relatedItem><identifier type="istex">9C448C47012553C0CA49E602AB1F33011679209C</identifier><identifier type="DOI">10.1002/mds.20563</identifier><identifier type="ArticleID">MDS20563</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2005 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001933 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001933 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:9C448C47012553C0CA49E602AB1F33011679209C
|texte= Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |